A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway

Seiichi Hosaka, Keisuke Horiuchi, Masaki Yoda, Robert Nakayama, Takahide Tohmonda, Michiro Susa, Masaya Nakamura, Kazuhiro Chiba, Yoshiaki Toyama, Hideo Morioka

Research output: Contribution to journalArticle

24 Citations (Scopus)


Synovial sarcoma is an aggressive soft tissue sarcoma with only a modest response to conventional cytotoxic agents. In the present study, we evaluated the potential antitumor effects of a novel anti-angiogenesis agent, pazopanib, against synovial sarcoma cells. We found that pazopanib directly inhibited the growth of synovial sarcoma cells by inducing G1 arrest. Multiplex analyses revealed that the PI3K-AKT pathway was highly suppressed in pazopanib-sensitive synovial sarcoma cells. Furthermore, administration of pazopanib highly suppressed the tumor growth in a xenograft model. Taken together, these results suggest pazopanib as a possible agent against synovial sarcoma and may warrant further clinical studies.

Original languageEnglish
Pages (from-to)1493-1498
Number of pages6
JournalJournal of Orthopaedic Research
Issue number9
Publication statusPublished - 2012 Sep 1



  • PI3K-AKT pathway
  • molecular targeted therapy
  • pazopanib
  • synovial sarcoma

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this